Premarket Research Report Covering the Biotech Industry

LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

The Biotech industry is consistently improving, and has even trended higher over the past couple of weeks. Growth opportunities are opening up, making stocks in this space worthy of investors notice. Let us take a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions. Register with us now and access the full reports on these stocks at:

http://www.activewallst.com/register/

Incyte Corporation (NASDAQ: INCY)

Wilmington, Delaware headquartered Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology. Last Friday, the Company’s stock saw a correction of 3.14%, to close the day at $84.96 with a total volume of 1.20 million shares traded. The Company’s shares have advanced 23.69% in the last month and 18.02% over the previous three months. The stock is trading 12.13% above its 50-day moving average. Additionally, shares of Incyte have a Relative Strength Index (RSI) of 61.70.

Chimerix Inc. (NASDAQ: CMRX)

Shares in North Carolina-based Chimerix Inc., which discovers, develops, and commercializes oral antiviral in the areas of unmet medical needs in the U.S., finished Friday’s session at $4.78 which was a correction of 4.21% from its previous closing price. The stock recorded a trading volume of 851,645 shares. The Company’s shares are trading below their 50-day moving average by 9.53%. Furthermore, shares of Chimerix have an RSI of 42.53.

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX)

Texas-based biopharmaceutical Company, Lexicon Pharmaceuticals Inc.’s stock finished 1.88% lower at $14.62 last Friday at the close, and with a total volume of 481,092 shares traded. The Company’s shares have advanced 21.63% in the past month, 32.91% in the previous three months, and 9.84% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 11.05% and 22.15%, respectively. Additionally, shares of Lexicon Pharmaceuticals have an RSI of 63.08.

Synthetic Biologics Inc. (AMEX: SYN)

Shares in Rockville, Maryland headquartered Synthetic Biologics Inc., a clinical stage Company, ended last Friday’s session 0.95% lower at $2.09. The stock recorded a trading volume of 436,613 shares. The Company’s shares have advanced 4.50% in the last month and 13.59% over the previous three months. The stock is trading 4.90% below its 200-day moving average. Moreover, shares of Synthetic Biologics have an RSI of 42.84. On May 6th, 2016, research firm FBR Capital reiterated its ‘Outperform’ rating with a decrease of the target price to $9 a share from $10 a share for the Company’s stock.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom|
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: ActiveWallSt.com

ReleaseID: 440782